Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

Relief Ther­a­peu­tics, a Swiss, com­mer­cial-stage bio­phar­ma­ceu­ti­cal com­pa­ny iden­ti­fy­ing, devel­op­ing and com­mer­cial­iz­ing nov­el, patent pro­tect­ed prod­ucts in select­ed spe­cial­ty, rare and ultra-rare dis­ease areas on a glob­al basis, today announced that Pao­lo Galfet­ti has been pro­mot­ed to Chief Oper­at­ing Offi­cer, effec­tive Octo­ber 14, 2022. Pao­lo will con­tin­ue his respon­si­bil­i­ties as CEO of APR Applied Phar­ma Research SA (“APR”) and as a mem­ber of Relief’s Board of Directors.

“Pao­lo has decades of expe­ri­ence in the phar­ma­ceu­ti­cal sec­tor and has been an inte­gral part of the Relief man­age­ment team since the acqui­si­tion of APR last year, and this pro­mo­tion to Chief Oper­at­ing Offi­cer is a tes­ta­ment to his lead­er­ship,” stat­ed Raghu­ram (Ram) Sel­vara­ju, Ph.D., Chair­man of the Board of Direc­tors of Relief. “With our U.S com­mer­cial orga­ni­za­tion in place to exe­cute the U.S. launch of PKU GOLIKE, and as the com­pa­ny matures, we will con­tin­ue to lever­age Paulo’s exper­tise in busi­ness devel­op­ment, licens­ing, oper­a­tional strate­gic man­age­ment, clin­i­cal research, and phar­ma­ceu­ti­cal dis­cov­ery and development.”

 

Mr. Galfet­ti added, “I eager­ly antic­i­pate tak­ing a more active role at Relief and expand­ing my respon­si­bil­i­ties glob­al­ly. It is tru­ly a plea­sure to be part of such a col­lab­o­ra­tive group of ded­i­cat­ed pro­fes­sion­als. In par­tic­u­lar I look for­ward to con­tribut­ing to the exe­cu­tion of the company’s over­all growth strat­e­gy includ­ing the suc­cess­ful U.S. launch of PKU GOLIKE, pow­ered by our pro­pri­etary, Phys­iomi­mi Tech­nol­o­gy, and if approved, to the world­wide devel­op­ment and com­mer­cial­iza­tion of ACER-001 for Urea Cycle Disorders.”

Since the acqui­si­tion of APR by Relief in June 2021, Mr. Galfet­ti has served as Pres­i­dent of Relief Europe. He joined APR in 1995 as head of licens­ing and busi­ness devel­op­ment and was appoint­ed its Chief Exec­u­tive Offi­cer in 2002. Under his lead­er­ship, APR brought its flag­ship PKU GOLIKE fam­i­ly of prod­ucts onto the mar­ket and devel­oped a rich pipeline of prod­uct can­di­dates. Ear­li­er in his career, Mr. Galfet­ti was a found­ing part­ner, Chief Exec­u­tive Offi­cer, and board mem­ber of the Insti­tute for Phar­ma­co­ki­net­ic and Ana­lyt­i­cal Stud­ies AG (IPAS), a Swiss con­tract research orga­ni­za­tion, Chief Exec­u­tive Offi­cer, and board mem­ber of Far­ma Resa, an Ital­ian con­tract research orga­ni­za­tion, and a mem­ber of sev­er­al Phar­ma licens­ing groups. He is a Char­tered Finan­cial Ana­lyst and holds a bachelor’s degree in eco­nom­ics from the Com­mer­cial Uni­ver­si­ty Boc­coni, Milan, Italy.